Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -1.20% 20.50 24,801 14:39:25
Bid Price Offer Price High Price Low Price Open Price
20.00 21.00 20.75 20.50 20.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -0.94 -0.71 24.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:36:51 O 10,000 20.50 GBX

Skinbiotherapeutics (SBTX) Latest News

More Skinbiotherapeutics News
Skinbiotherapeutics Takeover Rumours

Skinbiotherapeutics (SBTX) Share Charts

1 Year Skinbiotherapeutics Chart

1 Year Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

Intraday Skinbiotherapeutics Chart

Intraday Skinbiotherapeutics Chart

Skinbiotherapeutics (SBTX) Discussions and Chat

Skinbiotherapeutics (SBTX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-06-26 15:36:5220.5010,0002,050.00O
2019-06-26 14:27:3520.697214.89O
2019-06-26 13:39:2720.05850170.43O
2019-06-26 10:56:5020.849,0801,891.82O
2019-06-26 10:56:3020.844,799999.87O
View all Skinbiotherapeutics trades in real-time

Skinbiotherapeutics (SBTX) Top Chat Posts

DateSubject
26/6/2019
09:20
Skinbiotherapeutics Daily Update: Skinbiotherapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 20.75p.
Skinbiotherapeutics Plc has a 4 week average price of 20.50p and a 12 week average price of 14.75p.
The 1 year high share price is 29.50p while the 1 year low share price is currently 12.25p.
There are currently 118,708,494 shares in issue and the average daily traded volume is 86,388 shares. The market capitalisation of Skinbiotherapeutics Plc is £24,335,241.27.
21/5/2019
10:42
judijudi: Some good news might help solidify the share price
21/5/2019
10:33
judijudi: I did tell you Happens every time there are predictions Seen it at Opti countless times and by the same people Nearly always the Kiss Of Death The share price should do your talking Only in my opinion
19/4/2019
15:19
best1467: Totally agree no mention of performance milestones no surprise,and the 18p exercise price is a disgrace if we we were trading at 6p then ok. If as cath put it stellar results from the trail yet they offer massive share options at no premium which is completely contradictory and shows a total lack of confidence on where the share price is heading, or this CEO as screwed them and us over either way it’s a disappointment.
18/4/2019
10:00
lord loads of lolly: The share options are an interesting one. True, the RNS states "Exercise is subject to achieving performance milestones set by the Company's board which are aligned to growth in shareholder value and commercialisation of the Company's SkinBiotix® technology." However, it also mentions they're exercisable in three equal tranches at at 18p per share, with exercise being no earlier than 24/36 months hence. Since SBTX's current share price is just over 18p, where's the growth in shareholder value?
08/4/2019
15:43
lord loads of lolly: As an indirect holder (via Opti), I've an interest in SBTX doing well. And I think it stands a very good chance in the medium term. But IMHO there's a lot of confirmation bias on this BB today. My 31 March posts suggested Cath's pre-results comments implied the trial wouldn't be 100% conclusive. My take on things was dismissed by some at the time. But for all the spin on here today, that's exactly where we're at now. I'm not saying today's RNS was bad, just that it wasn't 100% conclusive. So there's an element of uncertainty still, in terms of formulation tweaks that might well do the trick but can't be seen as a foregone conclusion. Today's share price (down just > 8% at the time of writing), is - I think - a more reliable indicator than some on here would have you believe.
29/3/2019
11:00
owenmo: SBTX are poised to deliver make or break trial results; if successful, the prospect of follow-on commercial deals is pretty-well assured and share price will respond. Late last Summer the share price touched on 29p when all of this was conjecture; the trials were only under way. With trials “due to finalise on schedule in Q1 2019” (i.e. presumably now finalised) two important things happened to elevate things above the realm of conjecture. Now don’t you think that if you were, say, Seneca, already a significant share-holder, and poised to inject a further £1.5m (which they did mid-Feb), or if you were Stuart Ashman boasting an enviable track record in medical devices among other things, not to mention an MBA and B.Sc. in business management and poised to nail your colours to the SBTX mast as CEO designate (which he did this very day), that you’d have kept your powder dry until you had an inkling that the trial results would come out the right way. And you can still buy into SBTX at a 40% discount to what you’d have paid before any of this promise surfaced! Where would you position these developments in terms of de-risking? You can buy-in at more or less the price paid by the £1.5m pros.
25/1/2019
12:26
incanus: With respect, we have already been told the key milestones have already been passed. The last study is only expect to confirm what the company already knows. The share price are at these levels for a number of reasons. Most investors thought the trials where expect to last no longer than october and with data produced in november. Sbtx change this in favour of a far more detailed study than originally thought. This should have demonstrated confidence in the tech. Then just as we are recovering after the realisation the study is going to take us right through to april and the shock of this, there was the eventual realisation this was a good thing and thus the shares rallied to another attempt at breaking the all time high of 30p. All was looking fine until some broker called turner and pope phoned some of their clients asking if they wanted Sbtx stock at 19p when the share price was 29p. This of course killed all momentum and confidence. This has never been explained to investors like me. I sold alot of my shares on the leak placing news and only now have i decided to buy them back.
16/8/2018
14:58
mshilos: SBTX going below 20 p today and lower in the comings for reasons I explained in an earlier post below. In addition OPTI is now below £1 ...reason is as below : There is HUGE positive sentiment for OPTI and share price has soared recently on the back of this , but nothing more, no profit no HUGE contracts to report, no major news, etc, and NO PROFITS to report. They do have MASSIVE potential, if their LT plans are executed according to plan and they do have a great Founder/CEO. However, as a LT holder myself, since 27p I would expect the share price to fall to the 50-60 p levels before 2019 BUT to climb to over £2 in the next 2 years , if we keep moving in the right direction. It is only sentiment that is driven this share price at present, not profit, as there is no profit.IMO DYOR.
28/7/2018
17:00
speccy1: The more I think about it, the more sense it makes to place the OPTI held shares with an institutional investor and pay a cash divi. If the sale includes a lock-in period, it not only safeguards the SBTX share price, but given many of the OPTI investors would use their divi to buy SBTX, it could significantly improve the share price. The problem could then be everyone fighting to spend their divi at once and a mass charge causing a short term spike. It would be a terrible dilemma whether to buy straight away or hang fire until the initial rush for shares has died down. First World problems :)
21/4/2018
21:46
onedayrodders: I posted this on OPTI board but will be of interest here .. Hey all, myself and Trotters were at the UK Investor show today and were chatting with SOH for quite a while.. I'm sure Trotters will be posting a few nuggets later but I know the SBTX divi is an Important issue many have asked about so here is what he said. They are absolutely aware and focused on making this as fair as possible by not allowing short term traders to benefit or damage either OPTI or SBTX share price. Options being discussed ... 1. Lock in period - Unlikely as regulators do not like this type of arrangement and view it as restricting the market. 2. Staggered benefit, for example, OPTI will give shareholders say 1000 SBTX shares and promise another 1000 shares the next year providing the first 1000 shares have not been sold. 3. Take advantage of increasing interest in Skinbiotix by selling a % of OPTI's stake in SBTX to by Institutional investors and delivering a SBTX cash divi. (Therefore delivering the SBTX divi promise, adding long term Institutional shareholders and removing volatility in the share price - my take) The qualifying for any divi, either shares or cash will be controlled by a record date and that cannot be a date in the past and will be from close of business on the day the divi details are announced. So they will be looking to time that towards the end of the day to allow the smallest window possible for the AIM trading vultures (my words not his !) That's from memory so hope I got it right (Trotters..correct me if I'm wrong) ODR
Skinbiotherapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
SBTX
Skinbiothe..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 01:05:36